<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a double-blind, placebo-controlled, randomized crossover study, 15 stable mild hyperglycemic patients without treatment and with features of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> were treated with cerivastatin (0.4 mg/day) or placebo for 3 months </plain></SENT>
<SENT sid="1" pm="."><plain>The insulin sensitivity index during the euglycemic-hyperinsulinemic clamp (EHC; 5.4 mmol/l; 80 mU x m(-2) x min(-1)) was increased by cerivastatin treatment (66.39 +/- 3.9 nmol x lean body mass [LBM](-1) x min(-1) x pmol(-1) x l(-1)) as compared with placebo (58.37 +/- 3.69 nmol x LBM(-1) x min(-1) x pmol(-1) x l(- 1); P &lt; 0.01) by 13.7% </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> oxidation during EHC was significantly higher with <z:chebi fb="0" ids="35664">statin</z:chebi> treatment (16.1 +/- 1.37 micromol x LBM(-1) x min(-1)) as compared with placebo (14.58 +/- 1.48 micromol x LBM(-1) x min(-1); P &lt; 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>During <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> (approximately 800 pmol/l) in EHC steady-state, <z:chebi fb="23" ids="18059">lipid</z:chebi> oxidation was significantly decreased and respiratory quotient was significantly increased with <z:chebi fb="0" ids="35664">statin</z:chebi> treatment (0.33 +/- 0.05 mg x LBM(-1) x min(- 1), 0.94 +/- 0.01) as compared with placebo (0.48 +/- 0.06 mg x LBM(-1) x min(-1), 0.91 +/- 0.01; P &lt; 0.01 and P &lt; 0.05, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>During <z:chebi fb="0" ids="35664">statin</z:chebi> treatment, the first-phase insulin response increased from 2.07 +/- 0.28 to 2.82 +/- 0.38 pmol x l(-1) x pmol(-1) (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The second phase of insulin responses examined by C-<z:chebi fb="7" ids="16670">peptide</z:chebi> and insulin levels averaged during the hyperglycemic clamp (20 mmol/l) was unchanged </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, this study demonstrates that 0.4 mg cerivastatin therapy improves first-phase insulin secretion and increases insulin-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and respiratory quotient in the early state of <z:mp ids='MP_0001261'>obese</z:mp> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>